MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2 - a podcast by Clinical Care Options

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCLC with topics including:

• Whether testing for MET  exon 14 status should be standard of care
• Parallel vs sequential testing by DNA-based vs RNA-based NGS
• Co-occurring driver mutations in patients with METex14 mutation–positive NSCLC
• Optimal use of immune checkpoint inhibitor–based therapy in the setting of METex14-positive disease, including sequencing with MET inhibitor–based therapy
• EMA regulatory considerations for the new, selective MET inhibitors tepotinib and capmatinib

Presenters:
Luis Paz-Ares, MD, PhD 
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Link to full program, including associated downloadable slidesets:  https://bit.ly/2ExadCf

Further episodes of CCO Oncology Podcast

Further podcasts by Clinical Care Options

Website of Clinical Care Options